Wednesday, May 10, 2023

May 10, 2023 at 08:31PM OMISIRGE

Indicated for use in adults and pediatric patients 12 years and older with hematologic malignancies who are planned for umbilical cord blood transplantation following myeloablative conditioning to reduce the time to neutrophil recovery and the incidence of infection.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/zdK7wnm

No comments:

Post a Comment